Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC,European Journal of Clinical Investigation

当前位置： X-MOL 学术 › Eur. J. Clin. Investig. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC
European Journal of Clinical Investigation ( IF 5.5 ) Pub Date : 2021-08-14 , DOI: 10.1111/eci.13668
Federico Carbone _{1,

2} , Stefano Ministrini _{3,

4} , Aldo Bonaventura _{1,

5} , Alessandra Vecchié _{1,

5} , Silvia Minetti ₁ , Nicholas Bardi ₁ , Edoardo Elia ₆ , Anna Maria Ansaldo ₁ , Daniele Ferrara ₁ , Erika Rijavec ₇ , Maria Giovanna Dal Bello ₈ , Federico Biello ₉ , Giovanni Rossi ₈ , Marco Tagliamento _{8,

9} , Angela Alama ₈ , Simona Coco ₈ , Paolo Spallarossa ₁₀ , Francesco Grossi ₇ , Carlo Genova _{8,

9} , Fabrizio Montecucco _{1,

2}

Affiliation

First Clinic of internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, Genoa - Italian Cardiovascular Network, Genoa, Italy.
Center for Molecular Cardiology, Universität Zürich, Schlieren, Switzerland.
Internal Medicine, Angiology and Atherosclerosis, Department of Medicine and Surgery, Università degli Studi di Perugia, Perugia, Italy.
Division of Cardiology, Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
Division of Cardiology, Department of Internal Medicine, Città della Salute e della Scienza, Turin, Italy.
Medical Oncology Unit, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.
UOS Tumori Polmonari, IRCCS Ospedale Policlinico San Martino Genoa, Genoa, Italy.
Department of Internal Medicine and Medical Specialties (DiMI), University of Genova, Genoa, Italy.
Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino Genoa, Genoa, Italy.

High circulating levels of cellular adhesion molecules (CAMs) in non-small cell lung cancer (NSCLC) have been supposed to act as a negative prognostic factor. Here, we explored the predictive role of pre-treatment levels of CAMs in previously treated patients receiving nivolumab for NSCLC.

中文翻译：